Empirical Anti-MRSA vs Standard Antibiotic Therapy and Risk of 30-Day Mortality in Patients Hospitalized for Pneumonia

US-based cohort study of 88,605 hospitalisations for pneumonia did not find a mortality benefit for treatment with empirical anti –methicillin-resistant S aureus (MRSA) therapy vs standard antibiotics for any group of patients examined, even those with risk factors for MRSA.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news